Sera Prognostics Advances Neonatal Health with New Prematurity Risk Insights and Funding Success

Sera Prognostics Unveils New Insights on Prematurity Risk in Neonatal Health

Sera Prognostics Inc., recognized as The Pregnancy Company®, continues to spearhead advancements in maternal and neonatal health through innovative biomarker assessments. A significant development arises with the publication of the topline results from the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal Outcomes (PRIME) study. Presented at the Society for Maternal Fetal Medicine (SMFM) 2025 Pregnancy Meeting by Dr. Brian Iriye, the study reveals promising outcomes in reducing neonatal morbidity and hospital stays. These findings indicate that Sera’s efforts are not only on the cutting edge of prenatal health technology but are also yielding tangible benefits for mothers and their newborns.

The PRIME study's results highlight a 25% reduction in the neonatal morbidity and mortality index (NMI) among the modified intent-to-treat population, alongside an 18% decrease in the length of neonatal hospital stays. When considering the broader intent-to-treat population, the results are equally compelling, showing a 20% reduction in NMI and a 22% decline in NICU admissions. These statistics underscore the potential impact of Sera's PreTRM test, which identifies women at risk of preterm birth, allowing for timely clinical interventions that can significantly improve neonatal outcomes. This research reinforces Sera’s commitment to enhancing healthcare strategies for pregnancy management, addressing one of the most critical challenges in maternal and neonatal health.

In light of these developments, Sera Prognostics is poised for growth, having successfully raised $57.5 million through a public follow-on offering. This funding extends the company’s cash runway through 2028, enabling further investment in commercial efforts within the U.S. market and potential expansion into the European Union. The company's President and CEO, Zhenya Lindgardt, emphasizes the importance of this technology in tackling the pressing societal and healthcare issues associated with premature births, indicating a strategic focus on collaboration with payers and providers to enhance the adoption of the PreTRM test.

In the financial report for the fourth quarter of 2024, Sera noted revenues of $24,000, a decline from $41,000 in the previous year. Despite this downturn, the company remains optimistic about its future prospects and the continuing relevance of its innovative solutions in the maternal and neonatal healthcare landscape. As Sera Prognostics moves forward, its commitment to improving pregnancy outcomes through scientific advancements positions it as a significant player in this vital sector.